Intraarticular drug delivery in osteoarthritis

Osteoarthritis (OA) is a primarily non-inflammatory, degenerative joint disease characterized by progressive loss of articular cartilage, subchondral bone sclerosis, osteophyte formation, changes in the synovial membrane, and an increased volume of synovial fluid with reduced viscosity and hence cha...

Full description

Saved in:
Bibliographic Details
Published in:Advanced drug delivery reviews 2006-05, Vol.58 (2), p.226-242
Main Authors: Gerwin, Nicole, Hops, Caroline, Lucke, Andrea
Format: Article
Language:English
Subjects:
Animals
Chemistry, Pharmaceutical
Glucocorticoid
Glucocorticoids - administration & dosage
Glucocorticoids - therapeutic use
Humans
Hyaluronic acid
Hyaluronic Acid - administration & dosage
Hyaluronic Acid - therapeutic use
Injections, Intra-Articular
Intraarticular
Joints - pathology
Joints - physiopathology
Osteoarthritis
Osteoarthritis - drug therapy
Osteoarthritis - pathology
Sustained release
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Osteoarthritis (OA) is a primarily non-inflammatory, degenerative joint disease characterized by progressive loss of articular cartilage, subchondral bone sclerosis, osteophyte formation, changes in the synovial membrane, and an increased volume of synovial fluid with reduced viscosity and hence changed lubrication properties. As OA is the most common type of arthritis and a leading cause of disability, there is a largely unmet medical need for disease-modifying and symptomatic treatment. Due to the localized nature of the disease, intraarticular (IA) drug injection is an attractive treatment approach for OA. The various glucocorticoid and hyaluronic acid (HA) formulations, which are currently available on the market for IA treatment, provide only short-term pain relief or/and often do not provide adequate pain relief. The available oral drugs for symptomatic treatment also have shortcomings, most notably side effects. Therefore, there is still a large unmet need for novel OA drugs, which provide effective long-term pain relief and/or have disease-modifying properties. To achieve long-term drug exposure, different established formulations such as suspensions and hydrogels, and also novel approaches such as lipid based formulations and nano- or microparticles are currently in development. The development of novel drugs in combination with new formulations for IA treatment of OA, represents a promising approach in this challenging area of research.
ISSN:0169-409X
1872-8294
DOI:10.1016/j.addr.2006.01.018